CITIC SEC: Innovative Drug Medical Insurance Access and Renewal Rules Further Improved, Commercialization Expectations Becoming Clearer
The national medical insurance negotiations continue the policy direction of supporting innovation, with the inclusion of new products, expansion of indications, and supporting hospital-access and payment measures jointly driving commercialization growth through 2027.
CITIC SEC released a research report stating that the national medical insurance negotiations continue the policy direction of supporting innovation, with new variety inclusion, indication expansion, and hospital access/payment support jointly driving commercialization growth in 2027. The new catalog announced on November 14, 2026 added 107 drugs, including 51 Class 1 innovative drugs, setting a new record, and CAR-T was included in basic medical insurance for the first time. This adjustment improved the pre-declaration and commercial insurance-to-basic medical insurance linkage, further clarified long-term renewal rules, and advanced drug hospital access and "dual-channel" supply.
CITIC SEC's main views are as follows:
Access and renewal rules further improved, long-term commercialization expectations for innovative drugs clearer.
In 2026, a pre-declaration mechanism was added, allowing drugs or indications that completed technical review by June 10 to pre-fill declarations, with approval materials supplemented by July 3; commercial insurance catalog drugs can apply for basic medical insurance, and 2 varieties were transferred this time. For exclusive drugs that have been continuously included in the negotiation catalog for 8 years and whose agreements expire in the current year, the payment standard adjustment method when transferring to the routine catalog was further clarified. The bank believes that the improvement of declaration linkage and pricing rules will help reduce access timing mismatches and enhance the predictability of long-term operations for enterprises.
Hospital access and payment support advanced simultaneously, focus on conversion from catalog access to prescription volume.
Newly added drugs must complete online listing by the end of 2026, and medical institutions in principle should hold pharmacy affairs meetings by the end of February 2027, equip as needed or open temporary procurement channels; localities should simultaneously update the "dual-channel" and separate payment scope, and cases unsuitable for payment by disease type standards can apply for special case single review. The new catalog will be implemented from January 1, 2027, and reimbursement must comply with label indications, medical insurance restricted payment scope, and local benefit policies. The above arrangements are expected to lower patient medication thresholds and promote the conversion of newly added medical insurance coverage into actual usage.
Among publicly comparable samples, over 80% of expiring renewed drugs maintained original prices, with price cuts involving 14 drugs.
Comparing item by item according to the 2025 and 2026 publicly disclosed payment standards, a total of 136 drugs and 187 records with the same name and specification were comparable. Among them, 64 drugs were expiring renewals, 52 maintained original prices, accounting for 81.3%; 70 drugs had original agreements continuing in effect without price adjustments; the remaining 2 agreements had not yet expired but both had price cuts. A total of 14 drugs had price cuts, involving 20 specifications, of which 12 drugs were expiring renewals and 2 were adjustments during the agreement period.
According to company disclosure standards, 4 INNOVENT BIO products were included for the first time, and 2 insured drugs added 3 indications (including co-promoted products); 3 SBP GROUP products were included for the first time, and 2 insured drugs added 6 indications (including 1 licensed product); 3 Jiangsu Hengrui Pharmaceuticals products were included for the first time, and 2 insured drugs added 2 indications. 1 Kelun-Biotech product was included for the first time, and 1 insured drug added 2 indications; REMEGEN's telitacicept prefilled syringe was included for the first time, and 2 other insured drug indications were newly included. Newly added varieties and indication expansions of existing products are expected to jointly support domestic sales growth of relevant enterprises in 2027.
CAR-T entered basic medical insurance for the first time, cell therapy accessibility expected to improve.
JW Therapeutics' relma-cel became the first CAR-T product included in basic medical insurance, providing new treatment opportunities for patients previously constrained by payment capacity. A total of 2 varieties from the original commercial insurance catalog were transferred to basic medical insurance this time, and after transfer, the relevant support policies of the original commercial insurance catalog still apply for 4 years, further clarifying the pathway for high-value innovative drugs to transition from commercial insurance to basic medical insurance. The bank believes that this change is expected to increase domestic CAR-T treatment penetration. CARsgen's CT041 was included in the commercial insurance innovative drug catalog this time.
ADC medical insurance payment scope expanded to earlier treatment lines and more cancer types, expected to drive domestic sales growth.
Kelun-Biotech's sac-TMT added the indication of EGFR-mutant non-squamous NSCLC after progression on EGFR-TKI treatment, moving earlier compared with the original payment scope of "after EGFR-TKI and platinum-containing chemotherapy"; it also added HR+/HER2 breast cancer that has received endocrine therapy and at least first-line chemotherapy in the advanced stage. Jiangsu Hengrui Pharmaceuticals' rezetecan, on the basis of the original HER2-mutant NSCLC payment scope, added locally advanced or metastatic HER2-positive breast cancer previously treated with at least one anti-HER2 drug. In terms of new varieties, Kelun-Biotech's HER2 ADC trastuzumab botidotin was included in medical insurance for the first time, covering advanced HER2-positive breast cancer treated with anti-HER2 therapy; Sichuan Biokin Pharmaceutical's rhenium[188Re] lonidamine? Nothe text refers to , which achieved medical insurance inclusion in the year of launch, covering recurrent or metastatic nasopharyngeal carcinoma that has received at least second-line systemic chemotherapy and failed PD-(L)1 treatment. The bank believes that new variety access and indication expansion of existing products jointly expand the ADC medical insurance covered population, and with hospital equipping and prescription implementation, are expected to generate domestic sales increment in 2027.
New varieties in autoimmune, metabolic, and hematologic oncology entered medical insurance, expanding new patient sources.
REMEGEN's telitacicept added payment scope for active Sjgren's syndrome and primary IgA nephropathy at risk of progression, further expanding disease coverage. INNOVENT BIO's mazdutide was included for the first time for the adult type 2 diabetes indication, and picankibart simultaneously covered moderate-to-severe plaque psoriasis; mazdutide's weight-loss indication did not thereby obtain basic medical insurance reimbursement. In hematologic oncology, BeOne Medicines Ltd.'s sonrotoclax and ASCENTAGE's lisaftoclax were both included in the CLL/SLL payment scope after BTK inhibitor treatment, and sonrotoclax also covers R/R MCL patients meeting prior treatment requirements, expected to promote commercialization of domestic BCL-2 inhibitors.
Immunotherapy combination regimens expanded in medical insurance coverage, some bispecific varieties maintained stable renewal prices.
SBP GROUP's benmelstobart was included in medical insurance for the first time and covers 5 indications, and culmerciclib was also included for the first time; anlotinib and penpulimab added 5 and 1 medical insurance payment indications respectively, promoting combination regimens such as the "Defu combination" and "Shuang'an combination" to cover more patients. HENLIUS's serplulimab was included in medical insurance for the first time, covering all 5 approved indications. AKESO's ivonescimab and cadonilimab retained their original medical insurance payment scope. The bank believes that new variety inclusion and combination regimen expansion are expected to expand patient coverage and drive sales growth.
Risk warnings:
Risk of new drug R&D progress falling short of expectations or failure; risk of new drug approval progress falling short of expectations or non-approval; risk that post-marketing efficacy and safety of new drugs fall short of expectations; risk of product commercialization falling short of expectations and unfavorable sales; risk of changes in market competition landscape; risk of medical policy changes exceeding expectations, and risk of insufficient intellectual property protection scope.
Related Articles

RITAMIX (01936) proposes to change its dual foreign (Chinese) name to "Angtuo Intelligent Technology Co., Ltd."

ENVISION GREEN (01783) signs computing power service framework agreement, secures supply of over 30,000 GPUs; compliant computing power leasing logic strengthens, making the computing power leasing business more economical

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.
RITAMIX (01936) proposes to change its dual foreign (Chinese) name to "Angtuo Intelligent Technology Co., Ltd."

ENVISION GREEN (01783) signs computing power service framework agreement, secures supply of over 30,000 GPUs; compliant computing power leasing logic strengthens, making the computing power leasing business more economical

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.






